<DOC>
	<DOCNO>NCT01046279</DOCNO>
	<brief_summary>Prospective casecontrol study glioma patient undergoing treatment bevacizumab ( Avastin ) . At present data correlation occurrence arterial hypertension clinical outcome patient glioma anaplastic astrocytoma . We investigate whether glioma patient develop hypertension bevacizumab treatment well outcome term progression free survival , response rate overall survival equally treated patient remain normotensive . Moreover , describe dynamic change blood pressure administration bevacizumab patient develop hypertension . - Trial medicinal product</brief_summary>
	<brief_title>Hypertension Monitoring Glioma Patients Treated With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion : Patients age 18 old histological diagnosis anaplastic astrocytoma ( WHO grade III ) glioma ( WHO grade IV ) Assigned bevacizumab treatment ( monotherapy adjunctive chemotherapy ) therapeutic reason oncologist Patients stable decrease dose steroid Willingness ability comply protocol Patient present KPS &gt; =70 Signed informed consent Exclusion criterion : Previous antiangiogenic drug bevacizumab Allergy hypersensitivity bevacizumab Contraindications bevacizumab accord Summary Product Characteristics Unwillingness comply regular assessment response performance studyrelated procedure Any condition consider relevant proper performance study risk patient , discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>